(Reuters) -AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped boost third-quarter results above Wall Street estimates.

The North Chicago-based drugmaker has been leaning on Skyrizi and Rinvoq to offset declining sales of its once best-selling arthritis treatment Humira that began facing biosimilar competition in the U.S. in 2023.

The company has poured more than $20 billion into acquisitions since then, and plans to spend another $10 billion on expanding within the United States over the next decade.

Global pharmaceutical companies are bolstering their U.S. manufacturing capacity after President Donald Trump urged the industry to make more medicines domestically rather than importing active ingredients or finished med

See Full Page